The effects of curcumin on mood, inflammation, and nicotine dependence in smokers Original paper

In this randomized controlled trial, supplementation with nanocurcumin was associated with favorable effects on inflammation but did not improve mood or nicotine dependence among smokers.

This Study Summary was published on February 8, 2024.

Quick Summary

In this randomized controlled trial, supplementation with nanocurcumin was associated with favorable effects on inflammation but did not improve mood or nicotine dependence among smokers.

What was studied?

The effect of nanocurcumin on cardiometabolic risk factors, mood, and nicotine dependence in smokers.

The primary outcomes were anxiety, depression, and nicotine dependence (assessed using the Beck Anxiety Inventory, Beck Depression Inventory, and Nicotine Dependence Syndrome Scale, respectively).

The cardiometabolic risk factors assessed were blood lipids, markers of glycemic control (fasting glucose, insulin, HOMA-IR), total antioxidant capacity, glutathione, high-sensitivity C-reactive protein (CRP), malondialdehyde (MDA), and nitric oxide (NO). (CRP is a biomarker of inflammation.[1] MDA and NO have been proposed as markers of inflammation and oxidative stress, but their diagnostic values are not as well established.)[2][3].

Who was studied?

70 adults (average age of 33; 57 men, 15 women) in Iran. All of the participants reported a dependence on nicotine and had been smoking for an average of 11 years.

How was it studied?

In this 12-week randomized controlled trial, the participants supplemented with 80 mg of nanocurcumin or a placebo daily. The outcomes were measured at baseline and after 12 weeks.

What were the results?

CRP, MDA, and NO levels were reduced in the nanocurcumin group, compared with the placebo group. There were no other differences between the groups.

Anything else I need to know?

The researchers did not adjust for multiple comparisons, which increases the risk of false-positive results, so caution is warranted when interpreting the findings.

This Study Summary was published on February 8, 2024.

References

  1. ^Luan YY, Yao YMThe Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases.Front Immunol.(2018)
  2. ^Bahadoran Z, Mirmiran P, Tahmasebinejad Z, Azizi F, Ghasemi ASerum nitric oxide metabolites and hard clinical endpoints: a population-based prospective study.Scand Cardiovasc J.(2019-Aug)
  3. ^Maryam Khoubnasabjafari, Khalil Ansarin, Abolghasem JouybanReliability of malondialdehyde as a biomarker of oxidative stress in psychological disordersBioimpacts.(2015)